The drug and biotech sector saw a strong first half of 2024, driven by an increase in mergers and acquisitions (M&A), robust earnings, and pipeline and regulatory successes. The Zacks Large Cap Pharmaceuticals industry rose 19.3% in the first half of 2024. However, there was a major downturn in the second half due to overall disappointing third-quarter sales and profits, guidance cuts, pipeline setbacks and the appointment of Robert F. Kennedy Jr., a vaccine skeptic, as the head of Health and Human Services ...

AbbVie Inc is a global biopharmaceutical company that specializes in the discovery, development, manufacturing, and marketing of advanced medicines.AbbVie focuses primarily on immunology, oncology, neuroscience, and virology treatments, and it has a broad portfolio of prescription drugs aimed at addressing a range of medical conditions. Humira (adalimumab), one of the world’s best-selling drugs, used to treat various autoimmune conditions. However, Humira’s patent expired in 2023, and AbbVie has been tr ...

iREIT+HOYA Capital is the premier income-focused investing service on Seeking Alpha. Our focus is on income-producing asset classes that offer the opportunity for sustainable portfolio income , diversification , and inflation hedging . Get started with a Free Two-Week Trial and take a look at our top ideas across our exclusive income-focused portfolios.It’s been quite some time since I covered AbbVie (NYSE: ABBV ) in my last article , back in October 2020, highlighting its undervaluation despite robust top ...

The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. AbbVie presently has an excellent rank, in the top 25% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.Start slideshow: 10 Oversold Dividend Stocks »But ma ...

AbbVie (ABBV) continued its acquisition spree with the announcement of a definitive agreement to acquire private biotech Nimble Therapeutics, which will add the latter’s lead pipeline candidate, an oral peptide IL23R inhibitor in preclinical development for psoriasis. The acquisition will strengthen AbbVie’s immunology pipeline.Nimble is also making oral peptide-based therapeutics for autoimmune diseases leveraging its proprietary peptide synthesis platform. To acquire Nimble, AbbVie will make a cash paymen ...

AbbVie (ABBV) announced that it has entered into a definitive agreement to acquire privately held biotech, Nimble Therapeutics. The impending acquisition will add Nimble’s lead preclinical asset and a pipeline of other novel oral peptide candidates with potential across several autoimmune diseases to AbbiVie’s Immunology pipeline. The acquisition also allows AbbVie to utilize Nimble's proprietary peptide synthesis platform to enable the discovery and optimization of oral peptide therapeutics.Nimble’s lead p ...

Proposed acquisition adds Nimble's lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for psoriasis, and a pipeline of other novel oral peptide assets across autoimmune diseases where significant unmet needs remain Acquisition also allows AbbVie to utilize Nimble's proprietary peptide synthesis platform to enable the discovery and optimization of oral peptide therapeuticsNORTH CHICAGO, Ill. and MADISON, Wis., Dec. 13, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Nimble T ...

This will go down in history as an incredible year for stocks. The S&P 500 hit a new all-time high 50 times. For perspective, there are about 250 trading days in the year. So, on average, the market made history every five days this year. This is excellent for existing portfolios, but makes it challenging to find bargains.Higher prices mean that dividend investors get lower yields on new positions. The key is to be selective and take advantage of dips in prices of high-quality dividend companies. AbbVie (AB ...

Join iREIT on Alpha today to get the most in-depth research that includes REITs, mREITs, Preferreds, BDCs, MLPs, ETFs, and other income alternatives. 438 testimonials and most are 5 stars. Nothing to lose with our FREE 2-week trial .The most common fear in the world is acrophobia, which is the fear of heights. According to Baptist Health , more than 6% of the global population has it.Analyst’s Disclosure: I/we have a beneficial long position in the shares of ABBV either through stock ownership, options, or ...

Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease, ALIA-1758, and novel blood-brain barrier (BBB)-crossing technology to strengthen neuroscience pipeline and R&D capabilitiesNORTH CHICAGO, Ill., Dec. 11, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Aliada Therapeutics. With the completion of the acquisition, Aliada is now a part of AbbVie.Aliada's lead investigational asset is ALIA-1758, an anti-pyroglutamate amyl ...